The KCNMA1 gene encodes the pore-forming α-subunit of the large-conductance Ca²⁺-activated potassium (BK) channel, a key regulator of cellular excitability and signaling. KCNMA1 antibodies are essential tools for detecting and studying the expression, localization, and function of BK channels in various tissues, including neurons, smooth muscle, and secretory cells. These antibodies are widely used in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to investigate BK channel roles in physiological processes such as vascular tone modulation, neurotransmitter release, and hormone secretion. Dysregulation of BK channels has been implicated in disorders like epilepsy, hypertension, and cancer, making KCNMA1 antibodies critical for both basic research and clinical studies. Validated antibodies specifically target distinct epitopes of the KCNMA1 protein, often verified using knockout controls or siRNA knockdown to ensure specificity. Some studies also focus on detecting disease-associated KCNMA1 variants, such as gain-of-function mutations linked to developmental delay or movement disorders. Researchers rely on these antibodies to explore BK channel interactions with auxiliary subunits (e.g., β-subunits) and their sensitivity to modulators like calcium, voltage, and pharmacological agents. Overall, KCNMA1 antibodies serve as indispensable reagents for unraveling the molecular mechanisms of BK channels in health and disease.